Agios Pharma (AGIO) Confirms Proof-of-Concept for Mitapivat (AG-348) Based on Preliminary Phase 2 Results in Patients with Non-Transfusion-Dependent Thalassemia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| AGIOS PHARM (NASDAQ: AGIO) | Delayed: 37.00 -0.19 (0.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $37.19 | 52 Week High | $71.49 | |||
| Open | $36.93 | 52 Week Low | $33.50 | |||
| Day High | $37.32 | P/E | N/A | |||
| Day Low | $36.10 | EPS | $-1.18 | |||
| Volume | 920,052 | |||||
